Differences in patient characteristics, disease-modifying treatment utilization, and relapse by race/ethnicity in Texas medicaid patients with multiple sclerosis

被引：0
|
作者：
Richards, K. M. [1 ]
Lawson, K. A. [1 ]
Nazareth, T. [2 ]
Yu, T. -C. [2 ]
Ko, J. J. [2 ]
Burton, E. [3 ]
Sasane, R. [2 ]
机构：
[1] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA
[2] Novartis Pharmaceut, Hlth Econ & Outcomes Res, E Hanover, NJ USA
[3] Novartis Pharmaceut, US Med Affairs, E Hanover, NJ USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P658
引用
收藏
页码：322 / 323
页数：2
相关论文
共 50 条
  • [41] Treatment discontinuation and restart among patients with multiple sclerosis using disease-modifying therapies
    Fox, R.
    Mehta, R.
    Pham, T.
    Park, J.
    Wilson, K.
    Bonafede, M.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 558 - 559
  • [42] Treatment patterns of multiple sclerosis patients treated with disease-modifying therapies in Puerto Rico
    Chia, J.
    Nunez, M.
    Hernandez, H.
    Jimenez, G.
    Ong, A.
    Hashemi, L.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 764 - 764
  • [43] Discontinuation of first-line disease-modifying therapy in relapse onset multiple sclerosis
    Coerver, E. M. E.
    Bourass, A.
    Wessels, M. H. J.
    van Kempen, Z. L. E.
    Jasperse, M. M. S.
    Tonino, B. A. R.
    Barkhof, F.
    Mostert, J.
    Uitdehaag, B. M. J.
    Killestein, J.
    Strijbis, E. M. M.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 74
  • [44] Relapse efficacy endpoints for the evaluation of disease-modifying therapies in clinical studies of multiple sclerosis
    O'Neill, Gilmore
    Polman, Chris
    Kappos, Ludwig
    Kappos, Ludwig
    Yang, Minhua
    Pace, Amy
    Panzara, Michael
    NEUROLOGY, 2007, 68 (12) : A240 - A240
  • [45] Disease-Modifying Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis: A Comparison of Their Efficacy for Reducing Relapse Rate
    Lingohr-Smith, M.
    Deitelzweig, C.
    Lin, G.
    Lin, J.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (1_SUPPL) : 34 - 35
  • [46] Treatment Patterns, Healthcare Resource Utilization, and Costs Among Medicare Patients with Multiple Sclerosis in Relation to Disease-Modifying Therapy and Corticosteroid Treatment
    Marie Sanchirico
    Amanda Caldwell-Tarr
    Pallavi Mudumby
    Lobat Hashemi
    Robert Dufour
    Neurology and Therapy, 2019, 8 : 121 - 133
  • [47] Treatment Patterns, Healthcare Resource Utilization, and Costs Among Medicare Patients with Multiple Sclerosis in Relation to Disease-Modifying Therapy and Corticosteroid Treatment
    Sanchirico, Marie
    Caldwell-Tarr, Amanda
    Mudumby, Pallavi
    Hashemi, Lobat
    Dufour, Robert
    NEUROLOGY AND THERAPY, 2019, 8 (01) : 121 - 133
  • [48] Sex differences in outcomes of disease-modifying treatments for multiple sclerosis: A systematic review
    Li, Rui
    Sun, Xiaobo
    Shu, Yaqing
    Mao, Zhifeng
    Xiao, Li
    Qiu, Wei
    Lu, Zhengqi
    Hu, Xueqiang
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 12 : 23 - 28
  • [49] Perspectives and experiences of Dutch multiple sclerosis patients and multiple sclerosis-specialized neurologists on injectable disease-modifying treatment
    Visser, Leo H.
    Heerings, Marco A.
    Jongen, Peter J.
    van der Hiele, Karin
    PATIENT PREFERENCE AND ADHERENCE, 2016, 10 : 659 - 667
  • [50] Stoppers and non-starters of disease-modifying treatment in multiple sclerosis
    Grytten, N.
    Aarseth, J. H.
    Espeset, K.
    Johnsen, G. B.
    Wehus, R.
    Lund, C.
    Haugstad, R. C.
    ACTA NEUROLOGICA SCANDINAVICA, 2013, 127 (02): : 133 - 140
12345